[1]李滢,周智涵,杨齐锋,等.中药治疗糖尿病肾病的伞状系统评价[J].华侨大学学报(自然科学版),2025,(1):71-78.[doi:10.11830/ISSN.1000-5013.202403027]
　LI Ying,ZHOU Zhihan,YANG Qifeng,et al.Umbrella Systematic Review of Chinese Medicine for Diabetic Nephropathy[J].Journal of Huaqiao University(Natural Science),2025,(1):71-78.[doi:10.11830/ISSN.1000-5013.202403027]
点击复制

中药治疗糖尿病肾病的伞状系统评价()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
期数:
2025年第1期
页码:
71-78
栏目:
出版日期:
2025-01-10

文章信息/Info

Title:
Umbrella Systematic Review of Chinese Medicine for Diabetic Nephropathy
文章编号:
1000-5013(2025)01-0071-08
作者:
李滢;  周智涵;  杨齐锋;  吴循循;  刁勇;  杨会勇
华侨大学 生物医学学院, 福建 泉州 362021
Author(s):
LI Ying;  ZHOU Zhihan;  YANG Qifeng;  WU Xunxun;  DIAO Yong;  YANG Huiyong
School of Biomedical Sciences, Huaqiao University, Quanzhou 362021, China
关键词:
糖尿病肾病;  中药;  Meta分析;  方法学;  质量评价
Keywords:
diabetic kidney disease;  traditional Chinese medicine;  Meta analysis;  methodology;  quality assessment
分类号:
R259
DOI:
10.11830/ISSN.1000-5013.202403027
文献标志码:
A
摘要:
通过计算机检索中国知网、万方数据库、中文科技期刊数据库、PubMed和Embase数据库,将30篇文献纳入2013-2023年中药治疗Ⅲ~Ⅳ期糖尿病肾病的系统进行评价。通过图表结合的形式展示证据分布特征,并以质量评价工具AMSTAR-2对文献质量进行评价。研究结果表明:发文量总体呈上升趋势,干预措施中黄芪与茯苓占中药成分的绝大部分;Meta分析整体质量都较低,部分关键条目表现不佳;中药治疗Ⅲ~Ⅳ期糖尿病肾病的Meta分析已经形成一定规模的证据群,但这些文献的方法学质量存在较大问题,之后的研究需要按照相应评价标准提高要求,并选用更具有代表意义的结局指标。
Abstract:
China National Knowledge Infrastructure(CNKI), Wanfang Data, China Science and Technology Journal Database(VIP), PubMed and Embase are searched by computer, and 30 articles are included in the systematic review of the treatment of stage Ⅲ-Ⅳ diabetic kidney disease with traditional Chinese medicine from 2013 to 2023. The distribution characteristics of evidence through a combination of charts and graphs are displayed, and the literature quality is evaluated using quality evaluation tool AMSTAR-2. The research results show that the number of publications is on the rise overall, of which Astragalus membranaceus and Poria cocos account for the vast majority of traditional Chinese medicine components in intervention measures. The overall quality of Meta analysis is relatively lower with some key items performing poorly. The Meta analyses of Chinese medicine for the treatment of stage Ⅲ-Ⅳ diabetic nephropathy has formed a certain sizeable evidence group, but there are some problems in the methodology quality of the literature. The requirements of subsequent researches need to be improved according to corresponding review standards, and more representative outcome indicators need to be chosen.

参考文献/References:

[1] 李凯阳,李保华.中医药治疗糖尿病肾病的研究进展[J].新疆中医药,2024,42(1):119-122.
[2] 赵明,何燕铭,张曾,等.中医药调节外泌体干预糖尿病肾脏疾病研究进展[J].中国中医药信息杂志,2024,31(4):183-186.DOI:10.19879/j.cnki.1005-5304.202303098.
[3] 靳贺超,顾悦,张圆圆,等.细胞焦亡与坏死性凋亡在糖尿病肾病中的作用及中医药干预研究进展[J].中国实验方剂学杂志,2022,28(3):58-67.DOI:10.13422/j.cnki.syfjx.20220336.
[4] 吕改,鲁冰,吕小草,等.基于网络平台的个性化管理对Ⅲ~Ⅳ期糖尿病肾病患者用药效果的影响[J].中国药物滥用防治杂志,2024,30(1):72-74,79.DOI:10.15900/j.cnki.zylf1995.2024.01.018.
[5] 黄赛娇,林意,卢艳,等.基于内质网应激探讨越婢加术汤对糖尿病肾病患者的治疗机制[J].广州中医药大学学报,2024,41(2):299-305.DOI:10.13359/j.cnki.gzxbtcm.2024.02.006.
[6] 吕嘉欣,刘阳,王楚翘,等.中药有效成分通过调控miRNA的表达治疗糖尿病肾病机制的研究进展[J].实用中医内科杂志,2024,38(4):64-67.DOI:10.13729/j.issn.1671-7813.Z20230322.
[7] MOGENSEN C E,SCHMITZ A,CHRISTENSEN C K.Comparative renal pathophysiology relevant to IDDM and NIDDM patients[J].Diabetes-Metabolism Researchand Reviews,1988,4(5):453-483.DOI:10.1002/dmr.5610040504.
[8] SHEA B J,REEVES B C,WELLS G,et al.AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J].British Medical Journal,2017,358:j4008.DOI:10.1136/bmj.j4008.
[9] 张方圆,沈傲梅,曾宪涛,等.系统评价方法学质量评价工具AMSTAR 2解读[J].中国循证心血管医学杂志,2018,10(1):14-18.
[10] 李伦,杨克虎,田金徽,等.一种新的证据总结方法: 证据图简介[J].中国循证儿科杂志,2011,6(3):230-232.
[11] 陈欢.益气养阴通络法治疗早期糖尿病肾病的Meta分析[D].沈阳:中医药大学,2020.
[12] 袁丽莎,张宁,杨荣禄,等.益气温阳活血法治疗糖尿病肾脏病Ⅲ~Ⅳ期的Meta分析[J].海南医学院学报,2022,28(2):140-147.DOI:10.13210/j.cnki.jhmu.20201228.001.
[13] 董必成.尿毒清颗粒联合ACEI或ARB治疗Ⅲ期糖尿病肾病的Meta分析[D].南昌:江西中医药大学,2021.
[14] 张美珍,郝晓晖,李艳杰,等.参芪地黄汤治疗早期糖尿病肾病13项随机对照试验的Meta分析[J].世界中西医结合杂志,2022,17(4):637-644,651.DOI:10.13935/j.cnki.sjzx.220401.
[15] 刘芬,王郁金,苏衍进,等.参芪地黄汤治疗气阴两虚型Ⅲ~Ⅳ期糖尿病肾病 Meta分析及GRADE评价[J].河北中医,2023,45(2):330-338.
[16] 金玉洁.解毒通络益肾法治疗消渴肾病的Meta分析及消渴肾安汤作用机制探讨[D].长春:长春中医药大学,2023.
[17] 马虹.中成药治疗糖尿病肾病的Meta分析及网络药理学研究[D].石河子:石河子大学,2023.
[18] LUO Ying,YANG Shikun,ZHOU Xun,et al.Use of Ophiocordyceps sinensis(syn. Cordyceps sinensis)combined with angiotensin-converting enzyme inhibitors(ACEI)/angiotensin receptor blockers(ARB)versus ACEI/ARB alone in the treatment of diabetic kidney disease: A Meta-analysis[J].Renal Failure,2015,37(4):614-634.DOI:10.3109/0886022X.2015.1009820.
[19] ZHENG Qiyan,LIU Weijing,WEI Wei,et al.The efficacy and safety of Chinese herbal medicine combined with ACEI/ARB fortreatment of incipient diabetic nephropathy: A meta-analysis[J].TMR Integrative Medicine,2018,2(1):7-29.
[20] 阮智超,倪博然,李家木,等.3种活血化瘀类中成药治疗糖尿病肾病Ⅲ期的系统综述[J].世界中医药,2023,18(2):206-210,220.
[21] XUE Gao,SHANG Jianwei,LIU Hongfang,et al.A meta-analysis of the clinical efficacy of TCM decoctions made from formulas in the liuwei dihuang wan categorized formulas in treating diabetic nephropathy proteinuria[J].Evidence-Based Complementary and Alternative Medicine,2018,2018:2427301.DOI:10.1155/2018/2427301.
[22] 唐雯,尚恒,何雪娟,等.活血益气类中药联合雷公藤多苷治疗糖尿病肾病的Meta分析[J].中国医疗设备,2017,32(增刊1):161-162.
[23] 常天瀛.肾炎康复片联合ARB类降压药治疗糖尿病肾病的系统评价[D].长春:长春中医药大学,2013.
[24] 赵洁,莫超,孟立锋,等.补阳还五汤治疗早期糖尿病肾病的疗效及安全性的Meta分析[J].中国中药杂志,2019,44(8):1660-1667.DOI:10.19540/j.cnki.cjcmm.20190109.001.
[25] LIU Xiaoyu,LIU Ling,CHEN Pinyi,et al.Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy: A systematic review based on a subgroup analysis[J].Journal of Ethnopharmacology,2018,151(2):810-819.DOI:10.1016/j.jep.2013.11.028.
[26] YANG Gangyi,ZHANG Min,ZHANG Min,et al.Effect of Huangshukuihua(Flos Abelmoschi Manihot)on diabetic nephropathy: A Meta-analysis[J].Journal of Traditional Chinese Medicine,2015,35(1):15-20.DOI:10.1016/s0254-6272(15)30003-0.
[27] 张云.百令胶囊联合ARB治疗糖尿病肾病的Meta分析[D].武汉:湖北中医药大学,2018.
[28] 陈硕,秦万里,赵文景.补脾益肾、化瘀消癥法治疗Ⅲ期糖尿病肾病有效性和安全性系统评价与Meta分析[J].环球中医药,2019,12(6):959-966.
[29] 陈硕,赵文景,王悦芬,等.补脾益肾、通络泄浊法联合ACEI/ARB类药治疗Ⅲ~Ⅳ期糖尿病肾病有效性和安全性系统评价与Meta分析[J].河北中医,2019,41(1):123-132.
[30] 姚志,郑启艳,张冬梅,等.黄葵胶囊联合ACEI/ARB治疗2型糖尿病肾病Ⅲ期蛋白尿系统评价[J].中国中医药信息杂志,2019,26(9):99-103.
[31] 杨涛,李潇然,王世东,等.活血消癥中药治疗糖尿病肾病的随机对照临床试验系统综述及Meta分析[J].世界中医药,2017,12(1):5-9,15.
[32] 杨涛.基于倾向评分匹配法的海昆肾喜胶囊治疗糖尿病肾病病例回顾性研究[D].北京:北京中医药大学,2018.
[33] 范婷.糖肾汤治疗早期糖尿病肾病临床观察及老年糖尿病肾病与衰弱的关联[D].北京:北京中医药大学,2020.
[34] 吕沈辉.益气养阴补肾活血法治疗糖尿病肾病Ⅲ期的Meta分析[D].武汉:湖北中医药大学,2020.
[35] 戴骁意,濮佳琦,孙沛霖,等.益气养阴活血方治疗早期糖尿病肾病的Meta分析[J].浙江中西医结合杂志,2018,28(8):699-702.
[36] 陈美玲,孙鲁英,孙卫卫,等.中药灌肠治疗Ⅳ期糖尿病肾病系统评价[J].中医学报,2020,35(12):2706-2712.DOI:10.16368/j.issn.1674-8999.2020.12.596.
[37] 周威,林添昌,张怡.中药联合治疗2型糖尿病结合肾病Meta分析[J].右江民族医学院学报,2020,42(6):778-785.
[38] 吴晓芸,董必成,刘丽婷,等.中药穴位贴敷佐治糖尿病肾病Ⅲ-Ⅳ期的Meta分析[J].中医药通报,2020,19(6):59-63.DOI:10.14046/j.cnki.zyytb2002.2020.06.018.
[39] 潘欣渝.中医药改善糖尿病肾病微炎症状态文献计量学分析及系统评价[D].苏州:中国中医科学院,2023.
[40] SARAN A,WHITE H.Evidence and gap maps: A comparison of different approaches[J].Campbell Systematic Reviews,2018,14(1):1-38.DOI:10.4073/cmdp.2018.2.

相似文献/References:

[1]徐韬,许瑞安.中药及其有效成分抗肿瘤作用机制研究进展[J].华侨大学学报(自然科学版),2009,30(4):359.[doi:10.11830/ISSN.1000-5013.2009.04.0359]
　XU Tao,XU Rui-an.Progress on Ati-Tumor Mechanism of Chinese Medicine and Its Active Ingredients[J].Journal of Huaqiao University(Natural Science),2009,30(1):359.[doi:10.11830/ISSN.1000-5013.2009.04.0359]

备注/Memo

备注/Memo:
收稿日期: 2024-03-16
通信作者: 杨会勇(1978-),男,副教授,博士,主要从事循证中医药临床评价的研究。E-mail:shyhy@hqu.edu.cn。
基金项目: 国家自然科学基金资助项目(82304762); 福建省自然科学基金资助项目(2022J05062); 福建省厦门市自然科学基金资助项目(3502Z20227041); 华侨大学科研基金资助项目(21BS126)
更新日期/Last Update: 2025-01-20